Polycystic Ovary Syndrome: A Contemporary Clinical Approach
2021
Аутори:
Bjekić-Macut, JelicaVukašin, Tamara
Velija-Ašimi, Zelija
Bureković, Azra
Zdravković, Marija
Andrić, Zoran
Branković, Marija
Crevar-Marinović, Slobodanka
Mandić, Tatjana
Stanojlović, Olivera
Vojnović-Milutinović, Danijela
Livadas, Sarantis
Mastorakos, George
Тип документа:
Чланак у часопису (Објављена верзија)
,
© 2021 Bentham Science Publishers
Метаподаци
Приказ свих података о документуАпстракт:
Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.
Кључне речи:
GLP-1 RA; SGLT2 inhibitors; genetic abnormalities; hyperandrogenism; insulin resistance; metformin; polycystic ovary syndromeИзвор:
Current Pharmaceutical Design, 2021, 27, 1-9Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200007 (Универзитет у Београду, Институт за биолошка истраживања 'Синиша Станковић') (RS-MESTD-inst-2020-200007)
DOI: 10.2174/1381612827666210119104721
ISSN: 1381-6128
PubMed: 33463457